High p62 levels promote the activation of NRF2, which in turn induces the transcriptional activation of the p62/SQSTM1 gene, further increasing p62 accumulation through a feed-forward loop [4,38,39], and, therefore, p62 can be considered a key pro-oncogenic regulator [6] to be targeted in anti-cancer therapy. This evidence concerns the gene SQSTM1 and cancer.